Dyanavel XR

ApprovedSmall molecule

RRochester Center for Behavioral Medicine

Dyanavel XR is one of 36 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Attention Deficit Hyperactivity DisorderActive, not recruiting

Attention Deficit Hyperactivity DisorderApproved

Active, not recruiting

Competition

Competitive Landscape

102 competitors in Attention Deficit Hyperactivity Disorder

#DrugCompanyPhaseTrials

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

2 2

Provigil

NNuvo Research GmbH

Phase 3

1 3

Catapres

Boehringer Ingelheim

Phase 3

1 4

OROS Oxybutynin

Johnson & Johnson

Phase 3

4 5

Ambien

PPurdue Pharma LP

Phase 3

1 6

Sunosi

AAxsome Therapeutics, Inc.

Phase 3

1 7

Ritalin

Pfizer

Phase 3

5 8

Cymbalta

Alnylam Pharmaceuticals

Phase 2

1 9

Adderall-XR

NNew River Pharmaceuticals

Phase 3

2 10

Concerta

Johnson & Johnson

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalRecruiting

Attention Deficit Hyperactivity Disorder

NCT06248229

Clinical

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder1 trial

A Trial of Dyanavel XR in Treating Co-occurring Fatigue Symptoms in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

Recruiting·RRochester Center for Behavioral Medicine·Phase 4·NCT06248229·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Dyanavel XR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dyanavel XR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dyanavel XR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rochester Center for Behavioral Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: RRochester Center for Behavioral Medicine

Dyanavel XR

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder1 trial

References

Drug Info

Quick Facts

Related News